Spironolcatone for acne treatment

Topical 5 percent spironolactone versus placebo in the management of acne vulgaris - A randomised controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/074120

Enrollment

Registered

2024-09-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris

Interventions

Intervention1: 5% spironolactone gel: 5% spironolcatone gel application twice a day for 6 weeks Control Intervention1: vehicle: Vehicle/placebo to be applied twice a day for 6 weeks

Eligibility

Inclusion criteria

Inclusion criteria: Female patients suffering from mild to moderate acne (Grade 1 and 2) Not on any topical or systemic treatment for last 1 month

Exclusion criteria

Exclusion criteria: Pregnant and lactating female severe acne comorbid disease

Design outcomes

Secondary

Measure	Time frame
Physcian global assessmentTimepoint: 6 weeks	—

Primary

Measure	Time frame
50% improvemnt in acne severityTimepoint: at 2 weeks, 4 weeks and 6 weeks	—

Countries

India

Contacts

Public ContactShekhar Neema

base Hospital

shekharadvait@gmail.com9830032821

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026